#Sweden #Gothenburg #sales report #Zinzino AB #Faun Pharma

Zinzino AB's Preliminary Sales Report: August 2026

In a remarkable showcase of performance, Zinzino AB (PUBL.) has released its preliminary sales report for August 2026, revealing a 16% increase in revenue year-over-year. The company's total revenue reached SEK 280.9 million compared to SEK 242.5 million in August 2025. This growth is an encouraging sign for the company and demonstrates its resilient position in the global market.

Highlights of the Report

Zinzino's overall revenue for the period accumulated from January to August 2026 shows an impressive growth of 22%, amounting to SEK 2,464.8 million compared to SEK 2,027.8 million during the same period last year. This consistent upward trajectory positions Zinzino as a strong player in the competitive landscape.

The revenue figures disclosed cover various regions that significantly contributed to this growth:

• - Nordics: SEK 23.6 million (down 13% YoY)
• - Central Europe: SEK 85.3 million (up 18% YoY)
• - East Europe: SEK 23.8 million (down 17% YoY)
• - South West Europe: SEK 44.2 million (up 11% YoY)
• - The Baltics: SEK 7.6 million (down 22% YoY)
• - North America: SEK 63.0 million (up 61% YoY)
• - South America: SEK 2.5 million (up 79% YoY)
• - Asia-Pacific: SEK 28.8 million (up 30% YoY)
• - Africa: SEK 2.1 million (no change)

The North American market showed exceptional growth, with its revenue increasing by 61%, indicating strong demand and effective strategic operations in that region. This region has contributed significantly, with a remarkable year-to-date total of SEK 531.8 million compared to SEK 333.9 million the previous year.

Challenges and Changes

Despite overall positive news, some areas saw setbacks. The Nordics and East Europe faced declines in their revenue, with the latter’s figures reflecting a 12% decrease year-to-date. In contrast, Central Europe emerged as a significant growth driver, achieving an impressive year-to-date uptrend of 32%. This highlights the shifting dynamics and consumer preferences in various regions, suggesting that Zinzino will need to adapt its strategies accordingly.

Faun Pharma, a subsidiary of Zinzino, reported external sales of SEK 1.3 million compared to SEK 3.4 million last year, experiencing a noteworthy decline. More attention may need to be directed toward revitalizing this part of the business.

Looking Ahead

As we move forward, Zinzino's management is optimistic about maintaining this momentum into the latter part of the year. The general growth trend across multiple regions points toward a healthily diversifying portfolio and responsiveness to market demand.

With a steadfast focus on innovation and customer satisfaction, Zinzino is poised to further enhance its market presence. Stakeholders can look forward to the upcoming detailed quarterly performance reviews for insights into strategies that the company will employ to navigate market challenges and leverage favorable conditions.

For inquiries, Dag Bergheim Pettersen, CEO, is available through +47 (0) 932 25 700, or via email at [email protected]
Fredrik Nielsen, CFO, can be reached at +46 707 900 174, or at [email protected]

This report reaffirms Zinzino's strengthened position as it strives for continuous growth and profitability within the global market space.